Impact of uricosurics on mortality outcomes in patients with COVID-19 : a systematic review and meta-analysis of randomized controlled trials
© The Author(s) 2024. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society..
OBJECTIVES: To determine risks associated with uricosurics in COVID-19 patients.
METHODS: A systematic review and meta-analysis was conducted by systematically searching electronic databases.
KEY FINDINGS: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94).
CONCLUSIONS: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The International journal of pharmacy practice - (2024) vom: 04. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kow, Chia Siang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 04.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/ijpp/riae003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36928173X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36928173X | ||
| 003 | DE-627 | ||
| 005 | 20240305232945.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240305s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ijpp/riae003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM36928173X | ||
| 035 | |a (NLM)38438314 | ||
| 035 | |a (PII)riae003 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of uricosurics on mortality outcomes in patients with COVID-19 |b a systematic review and meta-analysis of randomized controlled trials |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the Royal Pharmaceutical Society. | ||
| 520 | |a OBJECTIVES: To determine risks associated with uricosurics in COVID-19 patients | ||
| 520 | |a METHODS: A systematic review and meta-analysis was conducted by systematically searching electronic databases | ||
| 520 | |a KEY FINDINGS: The pooled analysis of the included trials revealed that the use of uricosurics was not associated with the risk of mortality (pooled odds ratio [OR] = 1.03, 95% confidence interval [CI]: 0.94-1.12). However, there is a potential mortality benefit associated with the use of ascorbic acid (pooled OR = 0.78, 95% CI: 0.65-0.94) | ||
| 520 | |a CONCLUSIONS: The findings confirmed the safety of uricosurics in COVID-19 patients, despite their potential to cause uric acid excretion, which may possess antioxidant properties | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a uricosuric | |
| 700 | 1 | |a Ramachandram, Dinesh Sangarran |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 700 | 1 | |a Thiruchelvam, Kaeshaelya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The International journal of pharmacy practice |d 1997 |g (2024) vom: 04. März |w (DE-627)NLM09159071X |x 2042-7174 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ijpp/riae003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 03 | ||